NARA Discovery
Article Details
← Back to Search Results
Journal Article

In vitro structure–activity relationships and forensic case series of emerging 2-benzylbenzimidazole ‘nitazene’ opioids

Liam M. De Vrieze; Sara E. Walton; Eline Pottie; Donna Papsun; Barry K. Logan; Alex J. Krotulski; Christophe P. Stove; Marthe M. Vandeputte
Archives of Toxicology · Vol. 98, Issue 9 · pp. 2999-3018 · 2024

Abstract

2-Benzylbenzimidazole ‘nitazene’ opioids are presenting a growing threat to public health. Although various nitazenes were previously studied, systematic comparisons of the effects of different structural modifications to the 2-benzylbenzimidazole core structure on μ-opioid receptor (MOR) activity are limited. Here, we assessed in vitro structure–activity relationships of 9 previously uncharacterized nitazenes alongside known structural analogues. Specifically, we focused on MOR activation by ‘ring’ substituted analogues (i.e., N -pyrrolidino and N -piperidinyl modifications), ‘desnitazene’ analogues (lacking the 5-nitro group), and N -desethyl analogues. The results from two in vitro MOR activation assays (β-arrestin 2 recruitment and inhibition of cAMP accumulation) showed that ‘ring’ modifications overall yield highly active drugs. With the exception of 4′-OH analogues (which are metabolites), N -pyrrolidino substitutions were generally more favorable for MOR activation than N -piperidine substitutions. Furthermore, removal of the 5-nitro group on the benzimidazole ring consistently caused a pronounced decrease in potency. The N -desethyl modifications showed important MOR activity, and generally resulted in a slightly lowered potency than comparator nitazenes. Intriguingly, N -desethyl isotonitazene was the exception and was consistently more potent than isotonitazene. Complementing the in vitro findings and demonstrating the high harm potential associated with many of these compounds, we describe 85 forensic cases from North America and the United Kingdom involving etodesnitazene, N -desethyl etonitazene, N -desethyl isotonitazene, N -pyrrolidino metonitazene, and N -pyrrolidino protonitazene. The low-to-sub ng/mL blood concentrations observed in most cases underscore the drugs’ high potencies. Taken together, by bridging pharmacology and case data, this study may aid to increase awareness and guide legislative and public health efforts.

Bibliographic Information

JournalArchives of Toxicology
PublisherSpringer
Publication Date2024-09-01
Publication Year2024
Volume98
Issue9
Pages2999-3018
Document TypeJournal Article
Print ISSN0340-5761
eISSN1432-0738
DOI10.1007/s00204-024-03774-7

Access Information

NARA Access Coverage1930-01-01~Current
Journal Homepagehttps://www.springer.com/journal/204
Publisher PageOpen Publisher Page
Full-text access depends on NARA's subscribed coverage and institutional access.